Authors

Charles M. Rudin, MD

Latest:

Investigational Agents in SCLC in the Second Line Setting and Beyond

Taofeek Owonikoko, MD, PhD, highlights investigational agents and ongoing clinical trials in SCLC he looks forward to.

Charles M. Rudin, MD, PhD

Latest:

Patient Profile 2: A 60-Year-Old Man with SCLC Progressing on First-Line Therapy

Vivek Subbiah, MD, MPH, presents the patient profile of a 60-year-old man with SCLC who progressed on frontline therapy.

Charles Powell, MD

Latest:

Optimizing the Management of ILD: Take-Home Messages

Experts highlight key messages regarding optimal identification and management of interstitial lung disease.

Charles Rudin, MD, PhD, Memorial Sloan Kettering Cancer Center

Charles Ryan, MD, Masonic Cancer Center

Charles S. Fuchs, MD

Latest:

Dr. Fuchs Discusses Immunotherapy in Gastric Cancer

Charles S. Fuchs, MD, MPH, director, Yale Cancer Center, physician-in-chief, Smilow Cancer Hospital, 2017 Giant of Cancer Care in Gastrointestinal Cancer, discusses immunotherapy in gastric cancer.

Charles S. Fuchs, MD, Dana-Farber Cancer Institute

Charles S. Fuchs, MD, Harvard Medical School

Charles W. Scarantino, MD, PhD

Latest:

Wireless Dosimetry

A new way to ensure your patients receive the proper radiation dose where they need it.

Charlie Gourley, PhD, MBChB

Latest:

Dr. Charlie Gourley on Olaparib Maintenance in Ovarian Cancer

Charlie Lustman

Latest:

Cancer Survivor Charlie Lustman Lives to Tell His Story

Keynote Presenter Cancer Survivor Charlie Lustman Lives to Tell His Story

Charlotte Kubicky, MD, PhD

Latest:

Dr. Kubicky on the Optimal Use of Radiation in Patients With Breast Cancer

Charlotte Kubicky, MD, PhD, associate professor of radiation medicine, School of Medicine, medical director, Tuality Oregon Health and Science Cancer Center, Oregon Health and Science University, discusses the optimal use of radiation in the treatment of patients with breast cancer.

Charlton A. Smith, MD

Latest:

Primary Radiation Therapy for Myeloid Sarcoma of the Porta Hepatis

Treating myeloid sarcoma at the porta hepatis with 24 Gy over 12 fractions is a well-tolerated treatment that achieved a complete, durable response with minimal toxicity.

Charu Aggarwal, MD

Latest:

Advancement in NSCLC Precision Medicine: Biomarker Testing

Explore the latest breakthroughs in precision medicine with a focus on biomarker testing and emerging targets in patients with non–small cell lung cancer.

Charu Aggarwal, MD, MPH, Hospital of the University of Pennsylvania

Charu Aggarwal, MD, MPH, University of Pennsylvania Hospital

Latest:

Trilaciclib: Treatment Considerations

Advantages associated with the administration of trilaciclib in appropriate patients receiving a chemotherapy-containing regimen for extensive-stage small cell lung cancer.

Chase Doyle

Latest:

Multiple Myeloma Transplant Trial Shows No Extra Benefit with Additions to Standard Therapy

According to the results of the phase III StaMINA trial evaluating posttransplant therapy in multiple myeloma, a second a round of chemotherapy or stem cell transplant does not improve progression-free survival or overall survival compared with the current standard course of treatment alone.

Chau Dang, MD

Latest:

Dr. Dang on Cardiac Safety With Pertuzumab/Trastuzumab in Early-Stage HER2+ Breast Cancer

Chau T. Dang, MD, discusses the safety profile of pertuzumab plus trastuzumab in patients with HER2-positive locally advanced, inflammatory, or early-stage breast cancer.

Che-Kai Tsao, MD

Latest:

Dr Tsao on the Role of Nivolumab Plus Cabozantinib in Advanced RCC

Che-Kai Tsao, MD, discusses key updates from the phase 3 CheckMate 9ER trial, and how these data clarify the role of nivolumab plus cabozantinib as a new standard of care in renal cell carcinoma.

Chelsea C. Pinnix, MD, PhD

Latest:

Combined Radiation Therapy and Checkpoint Inhibition in Lymphoma: A Case Report and Brief Review

The emergence of immune checkpoint inhibitors as an effective treatment strategy is a result of increased understanding of the elaborate relationship between tumor cells, their microenvironment and the host immune response.